Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (175)

2024

  1. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  2. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

  3. Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID)

    Surgical Oncology, Vol. 52

  4. The ‘BCLC upon progression’ classification: After repeated validation, it is time to incorporate it in trial design

    Liver International

  5. Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta-analysis

    Liver International, Vol. 44, Núm. 1, pp. 250-262

2023

  1. Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis

    Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804

  2. Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 901-924

  3. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  4. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

    HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6

  5. Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease

    Journal of Physiology and Biochemistry

  6. Mapping early serum proteome signatures of liver regeneration in living donor liver transplant cases

    BioFactors, Vol. 49, Núm. 4, pp. 912-927

  7. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 869-879

  8. Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial

    Journal of Clinical Oncology

  9. Partial Radiation Nephrectomy Using 90Y Resin Microspheres: A Treatment Option for Renal Tumors With Malignant Characteristics in Patients Not Candidates for Surgery

    Clinical Nuclear Medicine, Vol. 48, Núm. 11, pp. 960-962

2022

  1. A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits

    Scientific Reports, Vol. 12, Núm. 1

  2. A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers

    Panminerva medica, Vol. 64, Núm. 4, pp. 485-496

  3. Abdominal normothermic regional perfusion in controlled donation after circulatory determination of death liver transplantation: Outcomes and risk factors for graft loss

    American Journal of Transplantation, Vol. 22, Núm. 4, pp. 1169-1181

  4. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

    Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693

  5. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

    American Journal of Transplantation, Vol. 22, Núm. 6, pp. 1671-1682

  6. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9